Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies
The PhasED-Seq-based MRD assay has strong analytical and clinical performance in B-cell malignancies. Improved ctDNA detection methods such as this may improve patient outcomes through detection of residual disease or early relapse.
Authors
- Sandra Close
- Richard D. Hockett
- David M. Kurtz (ORCID: https://orcid.org/0000-0002-6382-4651)
- Nina Klimova (ORCID: https://orcid.org/0000-0001-7702-7787)
- L Hyland
Institutions
- Foresight Science & Technology (United States) (US)
Publication Details
- Journal
- Oncotarget
- Published
- 2025-05-09
- DOI
- https://doi.org/10.18632/oncotarget.28719
- Citations
- 6
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 5.62